MedTrace Logo

Immunological Measurement of Aspartate/Alanine Aminotransferase

NCT03562585 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 219

Last updated 2018-06-19

No results posted yet for this study

Summary

Previous reports have suggested that ALT-immunoglobulin complex was increased according to the severity of the liver disease, and high concentration of mAST and this might indicate a severely damaged liver. Immunoassay might be useful as a screening method in the differ-ential diagnosis of liver fibrosis according to patients. In this study, the efficacy of immunoas-say in the prediction of liver fibrosis in patients with chronic hepatitis B (CHB) was evaluated.

Conditions

  • Chronic Liver Disease and Cirrhosis

Interventions

DIAGNOSTIC_TEST

with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies

with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies

Sponsors & Collaborators

  • Chuncheon Sacred Heart Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-01
Primary Completion
2010-12-30
Completion
2017-03-02

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03562585 on ClinicalTrials.gov